AGEN
USDAgenus Inc. Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$3.840
Haut
$3.980
Bas
$3.700
Volume
0.33M
Fondamentaux de l'Entreprise
Capitalisation Boursière
126.8M
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
0.46M
Bourse
NCM
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus with a Buy and maintains $23 price target.
France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
Agenus Inc. (NASDAQ:AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory microsatellite‑stable
Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)
Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with...
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus with a Buy and maintains $23 price target.
Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight
Webcast details updated from the August 11th release Webcast on Wednesday, August 27, 2025 at 4:00 p.m. EST Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced an update to its
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.